Read more
7:14 PM · 7 January 2026

US Open: Nasdaq continue to climb📈Intel and Eli Lilly stocks surge

US100
Indices
-
-
Intel
Stocks
INTC.US, Intel Corp
-
-

The U.S. stock market is recording gains today, with Eli Lilly (LLY.US) and Intel (INTC.US) standing out the most. Recently, Nvidia raised its revenue forecast, which has clearly eased concerns about a “tech bubble” and the high valuations of the U.S. equity market. However, the S&P 500 is almost flat and DJIA is falling almost 0.4%

Other companies attracting investor attention include Applied Digital, Constellation Brands, and Caterpillar, due to earnings results or scheduled management presentations. On the other hand, SanDisk shares are down nearly 3% following a jump of almost 27% in the previous session.

Economic data

  • US ADP private payrolls showed slightly weaker-than-expected employment growth.

  • Factory orders in Neico dropped more sharply than anticipated.

  • JOLTS data indicated lower job vacancies.

  • Meanwhile, the ISM Services index came in higher than expected.

Following reports that Venezuela will deliver 30–50 million barrels of previously sanctioned crude to the U.S., oil prices remain near $60 per barrel globally. The increased supply from Venezuela could deepen the existing downward trend in oil prices and offset gains driven by geopolitical tensions. Lower oil prices support the stock market rally and ease inflation concerns.

Source: xStation5

US100 (H1 interval)

Source: xStation5

Eli Lilly on a Winning Streak

Eli Lilly shares are up nearly 4% on news of its acquisition of Ventyx Biosciences, a deal potentially exceeding $1 billion, according to the Wall Street Journal, citing sources familiar with the matter. The announcement could come imminently.

About Ventyx Biosciences:

  • Produces drugs for immunological and inflammatory diseases.

Acquisition goals for Eli Lilly:

  • Develop new therapies for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

  • Treatments for Parkinson’s disease.

  • Drugs addressing cardiovascular problems related to obesity.

Following the announcement, Ventyx shares surged over 50% in after-hours trading, reflecting investor optimism. Neither Eli Lilly nor Ventyx has commented on further commercial development talks. The acquisition aligns with Eli Lilly’s strategy to expand beyond its diabetes and obesity segments, strengthening its presence in immunology and neuroscience. Shares have reached near all-time highs today.

Source: xStation5

Intel Shares Surge

Intel shares are up nearly 7% after news of a new gaming-focused processor and platform.

  • Intel is developing a dedicated gaming processor.

  • A broader gaming platform combining hardware and software is also in the works.

  • The platform will be based on Intel Core Series 3 processors, forming the foundation for the new gaming lineup.

  • The company aims to strengthen its competitive position against AMD and Nvidia, which have been expanding their gaming processor portfolios for years.

  • Intel expects to capitalize on growing demand for high-performance gaming hardware.

Investors see the plan as promising, viewing it as a potential growth driver in the gaming segment. More details on the processor and platform are expected to be released later this year.

Sources: xStation5

8 January 2026, 9:10 PM

NY Fed Survey: higher inflation expectations, but also higher equity price expectations 📄🔎

8 January 2026, 8:24 PM

Micron Bets Billions on AI. Here’s What’s Driving the New Semiconductor Supercycle! 📈

8 January 2026, 7:02 PM

Cryptocurrencies sell-off 📉Ripple loses despite Amazon partnership

8 January 2026, 4:58 PM

Will the defense sector keep European stock markets afloat❓

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 2 000 000 investors from around the world